304am永利集团|·主頁(歡迎您)
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2024-07-11
Publication in Journal of Translational Medicine Highlighting Henlius' Dual HER2 Blockade Therapy Mechanism of Action
2024-07-10
Advances in HER2+ GC: Dual HER2 Blockade Therapy Presented on MED and ESMO GI
2024-07-04
Indonesian BPOM and KGbio Visit Henlius: Deepening Cooperation for Mutual Success
2024-07-02
Henlius Receives Approval in Japan for Phase 3 MRCT of Anti-PD-1 mAb Serplulimab Combo on First-Line mCRC
2024-06-28
Henlius Announces Successful Completion of Phase 1 Clinical Study of Daratumumab HLX15
2024-06-26
Henlius Shines at World ADC Asia 2024, Showcasing Its Innovative R&D Accomplishments in ADC Area
2024-06-21
IMF Chief Economist Visits Henlius: Witnessing China's Economic Vitality and Biopharmaceutical Innovation
2024-06-19
Results from the Preclinical Study of HLX99, an Innovative Neurodegenerative Diseases Therapeutic of Henlius Released at ENCALS Meeting 2024
2024-06-18
Henlius to Make Its Debut at the World ADC Asia 2024
1
2
3
4
5
...
8
